CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA

By Dr. Matthew Watson

Management expects the non-clinical and CMC sections of the BLA to be resubmitted to FDA in November

Read the original:
CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA

Related Post


categoriaGlobal News Feed commentoComments Off on CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA | dataOctober 28th, 2021

About...

This author published 4152 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research